ISCO (International Stem Cell) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 24, 2026)


ISCO International Stem Cell Corp ISCO
28 GF Score
Price $0.18
GF Value $0.13
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is International Stem Cell Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

International Stem Cell's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

ISCO vs ONCO, VRAX, LYRA: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, International Stem Cell's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

International Stem Cell Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, International Stem Cell's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where International Stem Cell's Margin of Safety % (DCF FCF Based) falls into.


ISCO
28GF Score
International Stem Cell Corp ISCO
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is International Stem Cell (ISCO) Overvalued in 2026?

Based on GuruFocus' analysis, International Stem Cell stock appears to be overvalued. The current stock price of $0.18 is trading 37% above its estimated GF Value™ of $0.13. GuruFocus considers International Stem Cell to be Significantly Overvalued.

Key valuation signals for ISCO:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: $0.13 vs. price of $0.18 (37% above fair value)
  • GF Score™: 28/100 with 4 warning signs

No single metric tells the full story. See the ISCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

International Stem Cell Business Description

Address 9745 Businesspark Avenue, San Diego, CA, USA, 92131
International Stem Cell Corp is a clinical-stage biotechnology company. It is focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities. The company develops different cell types from its stem cells that may result in therapeutic products. The clinical applications of the company include neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; Liver cells, which are used to treat a variety of congenital and acquired liver diseases; and retinal cells and three-dimensional eye structures. The company operates in three segments, the therapeutic market, the biomedical market, and the anti-aging market. The Biomedical products business segment accounts for the majority of revenue.
28GF Score

Get the complete analysis for ISCO

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.18
Price
$0.13
GF Value